EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye condition that can cause vision loss, according to Europe’s drug regulator.

The European Medicines Agency’s safety committee found that an eye condition called NAION is a “very rare” side effect of semaglutide, a key ingredient in diabetes and obesity drugs. It could affect as many as 1 in 10,000 people taking the medicines, it said Friday, adding that product labels must now be updated.